AKTX Projected Dividend Yield
Sponsored Adr New/Akari Therapeutics PLC ( NASDAQ : AKTX )Akari Therapeutics, Plc is a late-stage biotechnology company. Co. is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). It is conducting a clinical trial of subcutaneous nomacopan for the treatment of HSCT-TMA in pediatrics. 20 YEAR PERFORMANCE RESULTS |
AKTX Dividend History Detail AKTX Dividend News AKTX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |